Lin HM - Search Results

1

Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.

Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S. Camidge DR, et al. Among authors: lin hm. J Thorac Oncol. 2021 Dec;16(12):2091-2108. doi: 10.1016/j.jtho.2021.07.035. Epub 2021 Sep 16. J Thorac Oncol. 2021. PMID: 34537440 Free article. Clinical Trial.

2

Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer.

Reckamp K, Lin HM, Huang J, Proskorovsky I, Reichmann W, Krotneva S, Kerstein D, Huang H, Lee J. Reckamp K, et al. Among authors: lin hm. Curr Med Res Opin. 2019 Apr;35(4):569-576. doi: 10.1080/03007995.2018.1520696. Epub 2018 Oct 5. Curr Med Res Opin. 2019. PMID: 30286627

3

Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.

Kawata AK, Lenderking WR, Eseyin OR, Kerstein D, Huang J, Huang H, Zhang P, Lin HM. Kawata AK, et al. Among authors: lin hm. J Med Econ. 2019 Sep;22(9):924-935. doi: 10.1080/13696998.2019.1624080. Epub 2019 Jun 25. J Med Econ. 2019. PMID: 31125274 Free article. Clinical Trial.

4

Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA).

Lenderking WR, Lin H, Speck RM, Zhu Y, Huang H, Huang J, Kerstein D, Langer CJ. Lenderking WR, et al. Future Oncol. 2019 Aug;15(24):2841-2855. doi: 10.2217/fon-2019-0185. Epub 2019 Jul 31. Future Oncol. 2019. PMID: 31364872 Clinical Trial.

5

Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.

Lin HM, Pan X, Hou P, Allen S, Baumann P, Hochmair MJ. Lin HM, et al. Future Oncol. 2020 May;16(15):1031-1041. doi: 10.2217/fon-2019-0849. Epub 2020 Apr 27. Future Oncol. 2020. PMID: 32338548 Free article.

6

Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.

Lin HM, Pan X, Hou P, Huang H, Wu Y, Ren K, Jahanzeb M. Lin HM, et al. J Med Econ. 2020 Aug;23(8):894-901. doi: 10.1080/13696998.2020.1762620. Epub 2020 May 21. J Med Econ. 2020. PMID: 32347754 Free article.

7

Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.

Jahanzeb M, Lin HM, Pan X, Yin Y, Wu Y, Nordstrom B, Socinski MA. Jahanzeb M, et al. Among authors: lin hm. Oncologist. 2020 Oct;25(10):867-877. doi: 10.1634/theoncologist.2020-0011. Epub 2020 Jul 23. Oncologist. 2020. PMID: 32490560 Free PMC article.

8

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.

Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S. Camidge DR, et al. Among authors: lin hm. J Clin Oncol. 2020 Nov 1;38(31):3592-3603. doi: 10.1200/JCO.20.00505. Epub 2020 Aug 11. J Clin Oncol. 2020. PMID: 32780660 Free PMC article. Clinical Trial.

9

Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.

Jahanzeb M, Lin HM, Pan X, Yin Y, Baumann P, Langer CJ. Jahanzeb M, et al. Among authors: lin hm. Clin Lung Cancer. 2021 Jan;22(1):49-57. doi: 10.1016/j.cllc.2020.08.003. Epub 2020 Sep 18. Clin Lung Cancer. 2021. PMID: 33250347 Free article.

10

Garcia Campelo MR, Lin HM, Zhu Y, Pérol M, Jahanzeb M, Popat S, Zhang P, Camidge DR. Garcia Campelo MR, et al. Among authors: lin hm. Lung Cancer. 2021 May;155:68-77. doi: 10.1016/j.lungcan.2021.03.005. Epub 2021 Mar 9. Lung Cancer. 2021. PMID: 33744781 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

672 results

Search Page